Enter assignee name

% Expired Patents = 25.0

Forward Citations = 9

Loading Chart...

12 inventors (with patents filed for the assignee):

Zhenkun Ma (8 out of 40 patents)

Jing Li (7 out of 11 patents)

Susan Harran (5 out of 16 patents)

4. Charles Z Ding (5 out of 23 patents)

5. In Ho Kim (5 out of 7 patents)

6. Keith D Combrink (4 out of 8 patents)

7. Yafei Jin (4 out of 8 patents)

8. Keith P Minor (4 out of 6 patents)

9. Jamie C Longgood (4 out of 4 patents)

10. Yong He (2 out of 2 patents)

11. Daniel Denton (1 out of 1 patent)

12. Timothy W Morris (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 7265107 - Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes (2007-09-04),

2. 7256187 - Rifamycin C-11 oxime derivatives effective against drug-resistant microbes (2007-08-14),

3. 7250413 - C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes (2007-07-31),

4. 7247634 - Rifamycin derivatives effective against drug-resistant microbes (2007-07-24),

5. 7238694 - Rifamycin imino derivatives effective against drug-resistant microbes (2007-07-03),

6. 7229996 - Rifamycin derivatives (2007-06-12),

7. 7226931 - (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions (2007-06-05),

8. 7202246 - Spiro-rifamycin derivatives targeting RNA polymerase (2007-04-10),

Cumbre Pharmaceuticals Inc. is a leading biopharmaceutical company focused on developing innovative and life-changing medications. We specialize in oncology, rare diseases, and autoimmune disorders. Our mission is to improve the quality of life for patients through the development of novel therapies. With a team of dedicated scientists and researchers, we are committed to advancing medical science and bringing new treatment options to patients in need.

Profile summary based on public USPTO records.